Lyseng-Williamson, Katherine A. - In: PharmacoEconomics 29 (2011) 3, pp. 251-268
Posaconazole (Noxafil) is an oral, second-generation, extended-spectrum triazole whose approved indications include prophylaxis of invasive fungal disease (IFD) in immunocompromised patients. In pivotal head-to-head trials, posaconazole was significantly more effective in preventing IFD than...